Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 602 | 3q26.1 | BCHE | butyrylcholinesterase | |
Mouse | - | 603 | 3 E3 | Bche | butyrylcholinesterase | |
Rat | - | - | 2q32 | Bche | butyrylcholinesterase |
Previous and Unofficial Names |
Acylcholine acylhydrolase | Butyrylcholine esterase | CHE1 | Choline esterase II | cholinesterase |
Database Links | |
Alphafold | P06276 (Hs), Q03311 (Mm) |
BRENDA | 3.1.1.7 |
CATH/Gene3D | 3.40.50.1820 |
ChEMBL Target | CHEMBL1914 (Hs), CHEMBL2528 (Mm) |
DrugBank Target | P06276 (Hs) |
Ensembl Gene | ENSG00000114200 (Hs), ENSMUSG00000027792 (Mm), ENSRNOG00000009826 (Rn) |
Entrez Gene | 590 (Hs), 12038 (Mm) |
Human Protein Atlas | ENSG00000114200 (Hs) |
KEGG Enzyme | 3.1.1.7 |
KEGG Gene | hsa:590 (Hs), mmu:12038 (Mm) |
OMIM | 177400 (Hs) |
Orphanet | ORPHA118998 (Hs) |
Pharos | P06276 (Hs) |
RefSeq Nucleotide | NM_000055 (Hs), NM_009738 (Mm), NM_022942 (Rn) |
RefSeq Protein | NP_000046 (Hs), NP_033868 (Mm), NP_075231 (Rn) |
SynPHARM | 78671 (in complex with tacrine) |
UniProtKB | P06276 (Hs), Q03311 (Mm) |
Wikipedia | BCHE (Hs) |
Selected 3D Structures | |||||||||||
|
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||
|
1. Butini S, Campiani G, Borriello M, Gemma S, Panico A, Persico M, Catalanotti B, Ros S, Brindisi M, Agnusdei M et al.. (2008) Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. J Med Chem, 51 (11): 3154-70. [PMID:18479118]
2. Giacobini E. (2003) Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res, 28 (3-4): 515-22. [PMID:12675140]
3. Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, Greig NH. (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem, 49 (7): 2174-85. [PMID:16570913]
4. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem, 278 (42): 41141-7. [PMID:12869558]
5. Yu QS, Holloway HW, Luo W, Lahiri DK, Brossi A, Greig NH. (2010) Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem, 18 (13): 4687-93. [PMID:20627738]